Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026)

Treace Medical Concepts has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$18.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 13.61% year-over-year to -$18.2 million; the trailing twelve-month figure through Mar 2026 stood at -$58.9 million (down 10.33% YoY), and the FY2025 full-year result was -$56.7 million, down 1.12% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$18.2 million, down from -$6.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$619000.0 in Q4 2024, with the low at -$21.3 million in Q2 2024.
• Historically, Net Income towards Common Stockholders has averaged -$13.2 million across 5 years, with a median of -$15.4 million in 2024.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 90.29% — and 2025, when it plunged 989.66%.
• Treace Medical Concepts' Net Income towards Common Stockholders stood at -$4.4 million in 2022, then slumped by 44.54% to -$6.4 million in 2023, then jumped by 90.29% to -$619000.0 in 2024, then sank by 989.66% to -$6.7 million in 2025, then sank by 170.36% to -$18.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$18.2 million (Q1 2026), -$6.7 million (Q4 2025), and -$16.4 million (Q3 2025), per Business Quant data.